AlzeCure Pharma – ACD440 – A novel non-opioid analgesic

Agenda:

13:00 – Introduction to AlzeCure and today’s agenda – Martin Jönsson, CEO, AlzeCure

13:10 – Pain: background and medical needs – Rolf Karlsten, MD, PhD, Uppsala University Hospital

13:30 – ACD440: A novel non-opioid analgesic – Märta Segerdahl, MD, PhD, CMO, AlzeCure

13:45 – Q&A

14:00 – Final comments & Take Home messages – Martin Jönsson, CEO, AlzeCure

During the symposium, titled ”ACD440 – A novel non-opioid analgesic”, Dr. Karlsten will provide an overview of the area of pain. Märta Segerdahl, CMO and project manager, will also give an update on AlzeCure’s clinical phase II TRPV1 antagonist candidate, ACD440, which is being developed as a new topical treatment for patients with chronic neuropathic pain. In addition, Dr. Karlsten, together with AlzeCure’s CEO Martin Jönsson and CMO Märta Segerdahl, will answer questions about the company’s progress in the development of new pain treatments.